Clinical Trial: Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational [Patient Registry]
Official Title: Value of TFF3, SFRP4, Romo1 and NFKB as Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers
Brief Summary: This study evaluates the usefulness of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-κB as potential diagnostic and prognostic biomarkers in endometrial and ovarian carcinoma.
Detailed Summary:
Sponsor: Ilker Kahramanoglu
Current Primary Outcome: Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in discrimination of benign and malignant gynecologic disease [ Time Frame: 2 days ]
Original Primary Outcome: Same as current
Current Secondary Outcome: Efficacy of serum levels of trefoil factor 3 (TFF3), secreted frizzled related protein 4 (sFRP-4), reactive oxygen species modulator 1 (Romo1) and nuclear factor (NF)-Κb in predicting overall survival and disease-free survival [ Time Frame: 1 year ]
Original Secondary Outcome: Same as current
Information By: Istanbul University
Dates:
Date Received: April 4, 2017
Date Started: April 4, 2017
Date Completion: April 2018
Last Updated: April 7, 2017
Last Verified: April 2017